



Fresenius Medical Care

The World's Leading Renal Therapy Company

Annual General Meeting

Frankfurt am Main, May 11, 2010



Fresenius Medical Care

Agenda




Fresenius Medical Care

Accomplishments and Business Update

Global Leadership Position

Growth Strategy and Summary



Accomplishments for 2009



Fresenius Medical Care

We achieved record results and delivered our Target

Record revenue and earnings



Strong organic growth in all segments



Very strong cash flow development



Expanded our global market share



Focused on research, innovation and quality in dialysis



Fiscal Year 2009 Another Record Year



Fresenius Medical Care


\$ in millions	FY 2009	% growth
Revenue	11,247	+6 +9% at constant currency
Operating Income (EBIT)	1,756	+5
Net Income	891	+9

2009 Strong Revenue Growth in all Regions



Fresenius Medical Care

Total revenue increased 6% to \$11,247 m




Impressive Growth Continued



Fresenius Medical Care


Revenue

(in \$ million)



Net Income


(in \$ million)



We Created Jobs Worldwide



Fresenius Medical Care




Strengthened Balance Sheet



Fresenius Medical Care

Assets

Liabilities



Total in \$ million	14,920	15,821	14,920	15,821
-------------------------------	---------------	---------------	---------------	---------------


2009 Annual Dividend Proposal



Fresenius Medical Care

13th

Consecutive Dividend Increase Proposed




- Long-term, profit-oriented dividend policy
- Annual increase since foundation of the company
- Payout ratio in € at 30%

Share Price Development Last 12 Months



Fresenius Medical Care

In %, indexed, May 2009 = 100



Last 12 months

FME Ord. in €	+ 44%
FME Ord. in US\$	+ 41%
DAX Index	+ 29%
DJES Health Care	+ 22%

Fiscal Year 2009

FME Ord. in €	+ 11%
FME Ord. in US\$	+ 12%
DAX Index	+ 24%
DJES Health Care	+ 18%

Market Capitalization in €uro

May 2010	12.0 bn (+ 9%)
May 2009	11.0 bn (+11%)

Strong First Quarter 2010



Fresenius Medical Care

**Clearly on track for our 2010 guidance
and another record year**

\$ in millions

Q1 2010

% growth

Revenue

2,882

+13

+10%
at constant
currency

Operating Income (EBIT)

423

+7

Net Income

211

+7

Agenda



Fresenius Medical Care

Accomplishments and Business Update

Global Leadership Position

Growth Strategy and Summary




Global Presence Products & Services



Fresenius Medical Care



Walnut Creek U.S. Ogden U.S. Guadalajara Mexico Reynosa Mexico L' Arbresle France St. Wendel Germany Schweinfurt Germany Cremona Italy JiangSu China Buzen Japan Inukai Japan




Dialysis Services Worldwide – Number of Patients Treated 2009*




Fresenius Medical Care

North America



Latin America




* Based on company statements and estimates


**\$65
Billion
Market**

**We Lead in Every Major
Market, Treating more
than 195,000 Patients
Worldwide**

EMEA



Asia Pacific



** 13,606 patients including managed clinics


Market Position Globally



Fresenius Medical Care

1,895,000 Dialysis Patients in 2009

Dialysis patients treated in 2009 by company




Market Position by Major Product Groups




Fresenius Medical Care

	<u>Rank 1</u>	<u>Rank 2</u>	<u>Rank 3</u>
Dialyzers	FME	Gambro	Nipro
Dialysis machines	FME	Gambro	Nikkiso
Hemodialysis concentrates	FME	Fuso	Gambro
Bloodlines	FME	Gambro	Kawasumi
Peritoneal dialysis products	Baxter	FME	Pisa

Dialyzers



Dialysis machines



Produced more than ~85,000,000 Dialyzers in 2009

Agenda



Fresenius Medical Care

Accomplishments and Business Update

Global Leadership Position

Growth Strategy and Summary




Global View of Dialysis Patients



Fresenius Medical Care

Global prevalence increased by 80% over the last 10 years

ESRD patients per million population (p.m.p.)





Services – Reduction in Mortality

North America 2005 – 2009: 21%

Europe 2005 – 2009: 13%

Products – Bloodlines


Reynosa, Mexico 2002 – 2010:
85% Improvement in Quality

Achieved less than 3 complaints per million while
producing 73 million bloodlines per year

Development of Dialysis Patient Numbers



Fresenius Medical Care




- Renal failure persists worldwide
- Dialysis is the primary treatment modality on a global scale
- The number of global dialysis patients is expected to double by 2020

Continued Growth Opportunities



Fresenius Medical Care



Fiscal Year 2010 – Outlook



Fresenius Medical Care

\$ in millions

Revenue

> 12,000

Net income

\$950 - 980

Capital expenditures

\$550 - 680

Acquisitions

<= \$400

Strong growth expected for 2010

Summary



Fresenius Medical Care

Our global presence, growth and profitability is market leading

Vertical integration was and will be the best business model

There are many opportunities but also challenges

We will confidently continue to pursue our growth strategy, and we will remain vigilant with respect to:

Quality

Innovation

Corporate Ethics



Fresenius Medical Care



**Thank You
for your interest in
Fresenius Medical Care !**





Fresenius Medical Care

The World's Leading Renal Therapy Company

Annual General Meeting

Frankfurt am Main, May 11, 2010



Fresenius Medical Care



Fresenius Medical Care AG & Co. KGaA

Investor Relations

Else Kröner Str. 1

61352 Bad Homburg v.d.H.

Ordinary shares

WKN 578 580

ISIN DE0005785802

SEDOL1 5129074 DE

Oliver Maier

Head of Investor Relations & Corporate Communications

Tel.: +49-(0)6172-609-2601

Fax.: +49-(0)6172-609-2301

Email: oliver.maier@fmc-ag.com

Gerrit Jost

Tel.: +49-(0)6172-609-5216

Fax.: +49-(0)6172-609-2301

Email: gerrit.jost@fmc-ag.com

Terry L. Morris

Tel.: +1-800-948-2538

Fax.: +1-615-345-5605

Email: terry.morris@fmc-na.com